Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | USP1 | O94782 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13485646 | 0.87 | KDM4E (0.32) | KDM4EHPGDALDH1A1USP1 | |
| SCHEMBL1484456 | 0.82 | KDM4E (0.36) | KDM4EHPGDALDH1A1 | |
| SCHEMBL10204393 | 0.80 | KMT2A (0.32) | KDM4EHPGDALDH1A1XDHTLR7 | |
| SCHEMBL12752299 | 0.74 | ALDH1A1 (0.32) | KDM4EHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL10204443 | 0.73 | TSHR (0.33) | KDM4EHPGDALDH1A1TLR7MEN1 | |
| SCHEMBL10204378 | 0.73 | KDM4E (0.34) | KDM4EHPGDALDH1A1XDHMEN1 | |
| SCHEMBL10204455 | 0.72 | KCNH2 (0.32) | KDM4EHPGDALDH1A1XDHTLR7 | |
| SCHEMBL10204288 | 0.72 | TLR7 (0.33) | KDM4EHPGDALDH1A1XDHTLR7 | |
| SCHEMBL501544 | 0.72 | KDM4E (0.32) | KDM4EHPGDALDH1A1XDH | |
| SCHEMBL12752499 | 0.72 | KDM4E (0.37) | KDM4EHPGDALDH1A1XDHPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100034827-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100034827-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100034827-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | POLR2E, POLRMT, POLR2H | KDM4E 1269/4885HPGD 2279/4885ALDH1A1 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.